Skip to main content
SpringerLink
Log in

Perioperative Management of Anticoagulation and Antiplatelet Therapy

  • Chapter
  • First Online:
Precision Anticoagulation Medicine

  • 1211 Accesses

Abstract

The term bridging is often used to refer to the use of short-acting anticoagulant before and after elective surgery to ensure the continuity of anticoagulation and reduce thromboembolic risks. This chapter reviews the bridging strategies and the suggested approaches to switch between the different anticoagulants to ensure a proper continuity of anticoagulation. It also covers the bridging strategies for antiplatelet agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AC:

Anticoagulation

ADP:

Adenosine diphosphate

AF:

Atrial fibrillation

ASA:

Acetylsalicylic acid

CABG:

Coronary artery bypass grafting

CCS:

Canadian Cardiovascular Society

CHF:

Congestive heart failure

CHADS2:

Score system for anticoagulation in atrial fibrillation

CHA2DS2-VASc :

Score system for anticoagulation in atrial fibrillation

COX-1/2:

Cyclooxygenase-1/2

CVA:

Cerebrovascular accident

DES:

Drug eluting stent

DOACs:

Direct oral anticoagulants

DVT:

Deep vein thrombosis

HIT:

Heparin-induced thrombocytopenia

ICH:

Intracranial hemorrhage

ICD:

Implantable cardioverter-defibrillator

INR:

International normalized ratio

LMWH:

Low-molecular-weight heparin

LN:

Lymph node

M:

Month

PCC:

Prothrombin complex concentrate

PE:

Pulmonary embolism

PT:

Prothrombin time

PTT:

Partial thromboplastin time

TIA:

Transient ischemic attacks

UFH:

Unfractionated heparin

VKA:

Vitamin K antagonist

VTE:

Venous thromboembolism

References

  1. Peri-operative management of patients who are receiving warfarin © 2013 Thrombosis Canada, 2013. http://www.thrombosiscanada.ca/guides/pdfs/Warfarin_perioperative_management.pdf.

  2. Warfarin: Peri-operative management. © 2016 Thrombosis Canada http://thrombosiscanada.ca/wp-content/uploads/2016/09/14_Warfarin-Peri-Operative_2016Sept15-2.pdf.

  3. Guideline for the management of oral anticoagulation before and after elective surgery or procedures. http://anesthesiology.queensu.ca/assets/Clinical_Policies/Guidelines_for_Bridging_Anticoagulation_-_Oct_2013.pdf.

  4. Rechenmacher SJ, Fang JC. Bridging anticoagulation: primum non nocere. J Am Coll Cardiol. 2015;66(12):1392–403.

    Article  CAS  Google Scholar 

  5. Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL Jr, Ortel TL, Saxonhouse SJ, Spinler SA. A report of the American College of cardiology clinical expert consensus document task force 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2017;69(7):871–98.

    Article  Google Scholar 

  6. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;99:73–80. [PubMed 9884382].

    Article  Google Scholar 

  7. Messmore HL, Jeske WP, Wehmacher WH, et al. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Saf. 2003;26:625–41.

    Article  CAS  Google Scholar 

  8. Ansara AJ, Arif S, Warhurst RD. Weight based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. Ann Pharmacother. 2009;43:9–18.

    Article  CAS  Google Scholar 

  9. Argatroban package insert, GlaxoSmithKline September, 2009.

    Google Scholar 

  10. Argatroban, Pfizer Canada, revision June 25, 2013.

    Google Scholar 

  11. PRODUCT MONOGRAPH Pr PRADAXA® Dabigatran Etexilate Capsules 75 mg, 110 mg and 150 mg Dabigatran Etexilate, (as Dabigatran Etexilate Mesilate) Anticoagulant Boehringer Ingelheim Canada Ltd. 5180 South Service Road Burlington, ON L7L 5H4 BICL 0266 17, 18 and 19 Date of Revision: February 7, 2019.

    Google Scholar 

  12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83.

    Article  CAS  Google Scholar 

  13. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–44.

    Article  CAS  Google Scholar 

  14. PRODUCT MONOGRAPH PrXARELTO® rivaroxaban tablets 2.5 mg, 10 mg, 15 mg and 20 mg Anticoagulant (ATC Classification: B01AF01) Bayer Inc. 2920 Matheson Boulevard East Mississauga, Ontario L4W 5R6 Canada http://www.bayer.ca Date of Revision: September 18, 2018.

  15. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, et al. Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019; https://doi.org/10.1056/NEJMoa1814051.

    Article  CAS  Google Scholar 

  16. PRODUCT MONOGRAPH PrELIQUIS® apixaban tablets 2.5 mg and 5 mg Anticoagulant Pfizer Canada Inc. 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Bristol-Myers Squibb Canada Co. Montreal, Canada H4S 0A4 www.bmscanada.ca Date of Preparation: 23 October 2018.

  17. Lixiana product monograph. (Servier Canada Inc), July 26, 2017.

    Google Scholar 

  18. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    Article  CAS  Google Scholar 

  19. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable Ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing non-cardiac surgery. Circulation. 2016;134(10):e123–55.

    Article  Google Scholar 

  20. Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. Br J Anaesth. 2013;111(Suppl 1):i3–17.

    Article  Google Scholar 

  21. British Society of Hematology. Guidelines: Peri-Operative Management of Anticoagulation and Antiplatelet Therapy, October, 2016 https://b-s-h.org.uk/guidelines/guidelines/peri-operative-management-of-anticoagulation-and-antiplatelet-therapy/.

  22. Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, Graham M, Tandon V, Styles K, Bessissow A, Sessler DI, Bryson G, Devereaux PJ. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo non-cardiac surgery. Can J Cardiol. 2017;33(1):17–32.

    Article  Google Scholar 

  23. Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel GRobinson SD, Sibbald M, So DY, Wong GC, Abunassar JG, Ackman ML, Bell AD, Cartier R, Douketis JD, Lawler PR, McMurtry MS, Udell JA, van Diepen S, Verma S, Mancini GBJ, Cairns JA, Tanguay JF, members of the Secondary Panel. 2018 Canadian Cardiovascular Society/Canadian Association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2018;34(3):214–33.

    Article  Google Scholar 

  24. PRODUCT MONOGRAPH BRILINTA® ticagrelor tablets 60 and 90 mg Platelet Aggregation Inhibitor AstraZeneca Canada Inc. 1004 Middlegate Road Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Date of Preparation: October 25, 2018.

  25. PRODUCT MONOGRAPH PrEFFIENT® prasugrel (as prasugrel hydrochloride) tablets 10 mg Platelet Aggregation Inhibitor © ELI LILLY CANADA INC. 3650 Danforth Avenue Toronto, Ontario M1N 2E8 1–877–545-5972 www.lilly.ca Date of Revision: June 17, 2014.

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic and Lerner School of Medicine, Abu Dhabi, UAE

    Cherine El-Dabh

  2. Section of Gastroenterology, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada

    Joshua Nero

  3. Saskatoon Cancer Centre, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Hadi Goubran

Authors
  1. Cherine El-Dabh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua Nero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hadi Goubran
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Saskatoon Cancer Centre College of Medicine University of Saskatchewan, Saskatoon, SK, Canada

    Hadi Goubran

  2. Faculty of Medicine Cairo University, Giza, Egypt

    Gaafar Ragab

  3. College of Human Medicine Michigan State University, East Lansing, MI, USA

    Suzy Hassouna

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

El-Dabh, C., Nero, J., Goubran, H. (2020). Perioperative Management of Anticoagulation and Antiplatelet Therapy. In: Goubran, H., Ragab, G., Hassouna, S. (eds) Precision Anticoagulation Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-25782-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25782-8_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25781-1

  • Online ISBN: 978-3-030-25782-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation